Brevan Howard Capital Management LP Increases Holdings in Edwards Lifesciences Co. (NYSE:EW)

Brevan Howard Capital Management LP raised its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 276.1% in the fourth quarter, HoldingsChannel reports. The firm owned 11,867 shares of the medical research company’s stock after buying an additional 8,712 shares during the quarter. Brevan Howard Capital Management LP’s holdings in Edwards Lifesciences were worth $879,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Principal Financial Group Inc. increased its position in shares of Edwards Lifesciences by 2.2% during the third quarter. Principal Financial Group Inc. now owns 817,516 shares of the medical research company’s stock valued at $53,948,000 after buying an additional 17,647 shares during the period. Harbor Capital Advisors Inc. boosted its position in Edwards Lifesciences by 2.5% during the 4th quarter. Harbor Capital Advisors Inc. now owns 11,135 shares of the medical research company’s stock valued at $824,000 after acquiring an additional 273 shares in the last quarter. Jacobs & Co. CA grew its holdings in shares of Edwards Lifesciences by 2.3% during the 4th quarter. Jacobs & Co. CA now owns 125,728 shares of the medical research company’s stock worth $9,307,000 after acquiring an additional 2,828 shares during the period. Graypoint LLC bought a new position in shares of Edwards Lifesciences in the 4th quarter worth approximately $247,000. Finally, Czech National Bank lifted its stake in shares of Edwards Lifesciences by 4.2% in the 4th quarter. Czech National Bank now owns 127,881 shares of the medical research company’s stock valued at $9,467,000 after purchasing an additional 5,166 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Trading Down 0.5 %

EW stock opened at $74.67 on Friday. The firm has a fifty day moving average price of $71.43 and a 200 day moving average price of $71.47. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $95.25. The firm has a market cap of $43.89 billion, a PE ratio of 10.71, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of $0.60 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The business had revenue of $1.41 billion during the quarter, compared to analysts’ expectations of $1.40 billion. During the same period last year, the company posted $0.66 EPS. The business’s revenue was up 6.2% on a year-over-year basis. Sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Morgan Stanley upped their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 12th. StockNews.com upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Thursday. Canaccord Genuity Group boosted their price objective on shares of Edwards Lifesciences from $71.00 to $75.00 and gave the stock a “hold” rating in a research note on Friday, April 25th. Piper Sandler raised shares of Edwards Lifesciences from a “neutral” rating to an “overweight” rating and raised their target price for the company from $73.00 to $80.00 in a research note on Thursday, April 24th. Finally, Stifel Nicolaus raised Edwards Lifesciences from a “hold” rating to a “buy” rating and boosted their price target for the stock from $75.00 to $90.00 in a research report on Thursday, January 30th. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat, Edwards Lifesciences currently has a consensus rating of “Hold” and a consensus target price of $79.45.

Insider Transactions at Edwards Lifesciences

In related news, CEO Bernard J. Zovighian sold 5,980 shares of the business’s stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $74.91, for a total value of $447,961.80. Following the completion of the sale, the chief executive officer now owns 58,284 shares in the company, valued at approximately $4,366,054.44. The trade was a 9.31 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Daniel J. Lippis sold 400 shares of the firm’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $69.48, for a total value of $27,792.00. Following the transaction, the vice president now owns 22,588 shares in the company, valued at approximately $1,569,414.24. This represents a 1.74 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 77,833 shares of company stock worth $5,611,023. 1.29% of the stock is currently owned by insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.